Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVTX-801 in SLC35A2-CDG
NCT05402384Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of D-galactose in SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
D-galactose
03
Conditions
SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG)
Beyond the preview
Go deeper on NCT05402384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05402384.